Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation
Авдеев С. Н., Ненашева Н. М., Жуденков К. В., Петраковскайа В. А., Изюмова Г. В.
Пульмонология
Т. 28, Вып. 3, С. 341-358
Опубликовано: 2018
Тип ресурса: Обзор
DOI:10.18093/0869-0189-2018-28-3-341-358
Аннотация:
The article provides a review on prevalence, phenotypes, endotypes, and the control of severe bronchial asthma. Severe asthma is a widespread, heterogeneous disease that affects 5 - 20[%] of patients with bronchial asthma. Prevalence of severe asthma in Russia significantly exceeds the official statistics data, therefore it is necessary to maintain a national register of patients with severe asthma. The conventional therapy for severe asthma is not always effective due to the uncontrolled course of the disease and eosinophilic airway inflammation. The identification of asthma phenotype/endotype is reasonable to develop a personalized approach to treatment. This approach allows to achieve better control of the disease and to minimize the risk of asthma exacerbations, fixed airway obstruction and adverse effects of the pharmacological therapy. The main changes in the Global Strategy for Asthma Management and Prevention (GINA, 2018) concerning severe asthma therapy are highlighted in this a
Ключевые слова:
Asthma control; Biomarkers; Endotype; Eosinophils; Global Initiative for Asthma; Mepoli-zumab; Monoclonal antibodies; Omalizumab; Phenotype; Reslizumab; Severe asthma
immunoglobulin E; interleukin 5; omalizumab; reslizumab; airway obstruction; asthma; disease exacerbation; disease severity; human; morbidity; phenotype; prevalence; respiratory tract inflammation; Review; Russian Federation; treatment planning
Язык текста: Русский
ISSN: 0869-0189
Авдеев С. Н. Сергей Николаевич 1968-
Ненашева Н. М.
Жуденков К. В.
Петраковскайа В. А.
Изюмова Г. В.
Avdeev S. N. Sergej Nikolaevich 1968-
Nenasheva N. M.
Zhudenkov K. V.
Petrakovskaya V. A.
Izyumova G. V.
Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation
Текст визуальный непосредственный
Пульмонология
Научно-практический журнал "Пульмонология"
Т. 28, Вып. 3 С. 341-358
2018
Обзор
Asthma control Biomarkers Endotype Eosinophils Global Initiative for Asthma Mepoli-zumab Monoclonal antibodies Omalizumab Phenotype Reslizumab Severe asthma
immunoglobulin E interleukin 5 omalizumab reslizumab airway obstruction asthma disease exacerbation disease severity human morbidity phenotype prevalence respiratory tract inflammation Review Russian Federation treatment planning
The article provides a review on prevalence, phenotypes, endotypes, and the control of severe bronchial asthma. Severe asthma is a widespread, heterogeneous disease that affects 5 - 20[%] of patients with bronchial asthma. Prevalence of severe asthma in Russia significantly exceeds the official statistics data, therefore it is necessary to maintain a national register of patients with severe asthma. The conventional therapy for severe asthma is not always effective due to the uncontrolled course of the disease and eosinophilic airway inflammation. The identification of asthma phenotype/endotype is reasonable to develop a personalized approach to treatment. This approach allows to achieve better control of the disease and to minimize the risk of asthma exacerbations, fixed airway obstruction and adverse effects of the pharmacological therapy. The main changes in the Global Strategy for Asthma Management and Prevention (GINA, 2018) concerning severe asthma therapy are highlighted in this a